Moderna's positive melanoma read wasn't enough: intismeran plus Keytruda cut recurrence or death 42% vs Keytruda alone, with a 12.2-point two-year RFS gain, yet $MRNA sold off. The bar was high and va

What happened: Moderna, Inc. reported positive Phase 3 INTerpath-001 results for intismeran plus Keytruda in high-risk melanoma, but shares sold off on nuanced expectations. Key numbers: 42% relative reduction in recurrence or death; 12.2-point absolute improvement in two-year recurrence-free survival versus Keytruda alone; 35.81x forward revenue and 38.49x forward price-to-sales. Why it matters: The analyst maintains a Hold rating on MRNA, pending longer-term survival data and evidence that the mRNA platform can deliver across additional tumor types beyond melanoma.

Moderna, Inc. reported positive Phase 3 INTerpath-001 results for intismeran plus Keytruda in high-risk melanoma, but shares sold off on nuanced expectations.

The analyst maintains a Hold rating on MRNA, pending longer-term survival data and evidence that the mRNA platform can deliver across additional tumor types beyond melanoma.